StockDrifts LogoStockDrifts

Quad Medicine 464490

Company
쿼드메디슨Quad Medicine
Insiders
2
Buys
8
Total Value
₩379M ($263K)
Avg Return
+1.77%
Last Filing
2026-06-15

Quad Medicine (464490) has 8 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩379M ($263K) in reported transaction value. The earliest filing StockDrifts holds for Quad Medicine is dated 2025-12-12; the most recent is 2026-06-15. Across these filings the average return since disclosure is +1.77%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-31BUYMarket Buy
백승기
Baek Seung-gi
moving10.0K₩5,070-0.2%₩53M ($37K)
2026-08-25BUY주식매수선택권
황근배
Hwang Geun-bae
moving10.0K₩5,120-1.2%₩41M ($28K)
2026-08-25SELL기타
황근배
Hwang Geun-bae
moving-10.0K₩5,120+1.2%₩51M ($36K)
2026-07-22BUYMarket Buy
백승기
Baek Seung-gi
CEO670₩5,500+3.8%₩4M ($3K)
2026-07-21BUYMarket Buy
백승기
Baek Seung-gi
CEO1.2K₩5,620+1.6%₩7M ($5K)
2026-07-20BUYMarket Buy
백승기
Baek Seung-gi
CEO3.5K₩5,940-3.9%₩21M ($14K)
2026-07-16BUYMarket Buy
백승기
Baek Seung-gi
CEO1.8K₩6,000-4.8%₩11M ($8K)
2026-07-15BUYMarket Buy
백승기
Baek Seung-gi
CEO3.0K₩5,800-1.6%₩17M ($12K)
2026-07-14BUYMarket Buy
백승기
Baek Seung-gi
CEO5.2K₩5,400+5.7%₩28M ($20K)
2026-06-15BUYMarket Buy
백승기
Baek Seung-gi
CEO149₩7,730+0.0%₩1M ($800)
2026-06-12BUYMarket Buy
백승기
Baek Seung-gi
CEO1.7K₩7,800-0.9%₩14M ($9K)
2026-06-11BUYMarket Buy
백승기
Baek Seung-gi
CEO1.9K₩7,780-0.6%₩15M ($10K)
2026-06-10BUYMarket Buy
백승기
Baek Seung-gi
CEO10.0K₩7,880-1.9%₩79M ($55K)
2026-06-09BUYMarket Buy
백승기
Baek Seung-gi
CEO11.4K₩7,630+1.3%₩87M ($60K)
2026-04-24BUYMarket Buy
백승기
Baek Seung-gi
CEO6.0K₩13,230+4.3%₩79M ($55K)
2026-04-23BUYMarket Buy
김영흥
Youngheung Kim
moving4.0K₩13,020+6.0%₩53M ($37K)
2026-04-23BUYMarket Buy
백승기
Baek Seung-gi
CEO4.0K₩13,020+6.0%₩52M ($36K)
2026-02-02SELL기타
성길환
Seong Gil-hwan
moving-13.5K₩15,000-15.3%₩203M ($141K)
2026-02-02BUY주식매수선택권
성길환
Seong Gil-hwan
moving13.5K₩15,000+15.3%₩203M ($141K)
2026-02-02BUY주식매수선택권
김영흥
Youngheung Kim
moving18.0K₩15,000+15.3%₩270M ($188K)
2026-02-02SELL기타
김영흥
Youngheung Kim
moving-18.0K₩15,000-15.3%₩270M ($188K)
2026-02-01BUY신규선임
조현종
Hyeonjong Cho
moving10.0K₩15,000+15.3%₩150M ($104K)
2026-01-01BUY신규선임
나운성
Naunseong
moving25.2K₩14,500+19.3%₩365M ($254K)
2025-12-31SELL임원퇴임
허혜진
Hyejin Heo
moving-5.9K₩14,500-19.3%₩85M ($59K)
2025-12-12BUY신규상장
성길환
Seong Gil-hwan
moving13.5K₩17,630-1.9%₩238M ($165K)
2025-12-12BUYPROGRAM
현신애
Hyun Shin-ae
moving48.3K₩17,630-1.9%₩852M ($591K)
2025-12-12BUYPROGRAM
백승기
Baek Seung-gi
CEO2.2M₩17,630-1.9%₩38.5B ($26.7M)
2025-12-12BUYPROGRAM
전혜선
Jeon Hye-sun
moving52.5K₩17,630-1.9%₩926M ($643K)
2025-12-12BUYPROGRAM
박정환
Park Jeong-hwan
CTO441.0K₩17,630-1.9%₩7.8B ($5.4M)
2025-12-12BUYPROGRAM
김영흥
Youngheung Kim
moving18.0K₩17,630-1.9%₩317M ($220K)
2025-12-12BUYPROGRAM
김영흥
Youngheung Kim
moving45.0K₩17,630-1.9%₩793M ($551K)
2025-12-12BUYPROGRAM
황근배
Hwang Geun-bae
moving10.0K₩17,630-1.9%₩176M ($122K)
2025-12-12BUYPROGRAM
황근배
Hwang Geun-bae
moving10.0K₩17,630-1.9%₩176M ($122K)
2025-12-12BUYPROGRAM
허혜진
Hyejin Heo
moving5.9K₩17,630-1.9%₩104M ($72K)
2025-12-12BUY신규상장
성길환
Seong Gil-hwan
moving66.8K₩17,630-1.9%₩1.2B ($818K)

Frequently asked questions

Who has been buying Quad Medicine stock?
2 distinct insiders have filed 8 disclosed insider purchases in Quad Medicine (464490), most recently on 2026-06-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Quad Medicine have?
Quad Medicine has 8 buy-side and 0 sell-side disclosures on record, covering ₩379M ($263K) in total reported value, spanning 2025-12-12 to 2026-06-15.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.